Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by a non-cardiogenic pulmonary edema with bilateral chest X-ray opacities and hypoxemia refractory to oxygen therapy and low level of positive end-expiratory pressure (1).

Recently, a large observational study reported an ARDS prevalence of 10.4% of all ICU admissions and of 23.4% of all subjects receiving mechanical ventilation (2). Despite these alarming numbers, according to the most recent literature, ARDS is still under-recognized, undertreated, and associated with a mortality rate that in the most severe forms is close to 50% (2).

Among the few therapeutic approaches, Prone Positioning (PP) can be considered one of the oldest attempts, firstly pointed out in the last Seventies as a strategy to improve ventilation in respiratory failure settings (3). Since then, the understanding of the physiology and the effectiveness of PP has been dramatically deepening and at the present time, PP has been recognized as one of three interventions (not considering ECMO) that can actually improve patient survival in ARDS cases, along with lower tidal volume (6 mL/kg of predicted body weight Vt) and continuous intravenous infusion of neuromuscular blocking agent (cisatracurium for 48 hours).

The mechanisms underlying the efficacy of PP to improve outcome include the redistribution of lung densities with a recruitment of dorsal regions, increase of end-expiratory lung volume, an increase in chest-wall elastance, a reduction of alveolar shunts, and the prevention of ventilator-induced lung injury (VILI) by a better distribution of tidal volume (4).

Moreover, lung recruitment may explain the reduction in pulmonary vascular resistance and right heart dimensions observed in PP (5).

However, despite this strong physiological rationale, early randomized clinical trials that tested the efficacy of PP left clinicians with consistent uncertainty on its real benefits on mortality rates. Advocated mechanisms for this low efficacy were lack of inclusion of the most severe forms of hypoxemia, the “low dose” of PP administered (less than 6 h/d), and the lack of use of protective mechanical ventilation (6). Despite these limitations, the survival rate increased among subjects with most severe ARDS treated in prone position (7).

An important breakout on PP can be identified in the PROSEVA trial, that showed a major decrease in mortality rate at 28 and 90 days in subjects treated with PP (The 28-day mortality was 16.0% in the prone group and 32.8% in the supine group; 90-day mortality was 23.6% in the prone group versus 41.0% in the supine group) (8). This was a multi-center randomized controlled trial on early application of prolonged prone position (16 h/d) in subjects with severe ARDS. One of the main features of this trial was the attempt to sharply define ARDS severity and ventilation parameters cutoffs (PaO₂/FIO₂ <150, PEEP >5 cmH₂O, FIO₂ 0.6, with an average VT of 6.1 mL/kg of predicted
body weight).

In this perspective, the correct choice of patients and early initiation of prone therapy appear to be key factors for the success of this strategy. Although Munshi et al. (9) clearly stated that PP is likely to reduce mortality among patients with severe ARDS if applied for at least 12 hours daily, it was still unclear how this findings modified the actual clinical practice in the ICU settings. The LUNGSAFE study shows that the rate of its application is extremely low (16.3%) (2).

Doubts had arisen that this low rate could be explained on the base that clinicians still perceived the evidence level as weak. Other explanations could be that the process of moving a patient to a prone position is often considered as labor-intensive and, if not correctly performed, it can increase the risk of accidental removal of the endotracheal tube, drains, or catheters, as well as the development of pressure sores.

Under these circumstances, a study specifically designed to enlighten the present situation on prevalence of PP use and the perception of its effectiveness as well as the possible reasons for not using it, is by all means required and welcome.

Recently, Guérin and coworkers reported results of the APRONET trial (10). This is a prospective international prevalence study, performed on a single day four times in April, July and October 2016 and January 2017. Over this period, 6,723 patients in 141 ICUs from 20 countries (77% European) were screened. Eventually, 735 patients with ARDS were monitored for use of PP, gas exchange, ventilator settings and plateau pressure. Complications and reasons for not using PP were also recorded. The main finding was that 32.9% of patients with severe ARDS received PP, showing low complication rates and significant improvements in terms of oxygenation and driving pressure.

The APRONET trial is therefore the first work that focuses on the prevalence of the use of PP in a substantial number of ICU centers and countries and that filed a list of the reasons not to use it.

Can we say that the picture substantially changed since the LUNGSAFE trial? According to the Authors, the scenario has significantly progressed in the last two years. The study found that PP was used in 32.9% of severe ARDS patients with a low rate of complications and significant results in terms of oxygenation increase and driving pressure decrease. It is interesting to point out that counting the patients who met the Proseva criteria the rate of pronating rises to 40.2%. However, if we consider the overall population of the study (735 patients that fulfilled the ARDS criteria vs. 2,377 in the LUNGSAFE study), the rate of PP goes down to 13.7% (101 patients).

Can we consider this a reliable picture of the present use of PP in the daily practice? The study design may arise some reasonable doubts.

First, the prevalence data collection was based on four days distributed in different seasons of the year between April 2016 and January 2017. This could be a point of strength for the study when looking at the prevalence of ARDS cases on a seasonal base but on the other hand, each center had the freedom to choose to participate how many times as it could, and to join one or more of the predetermined days and it is therefore reasonable to think (and Authors pointed it up) that the prescheduling of the deadlines could have boosted the use of PP in anticipation of the participation to the study. In fact, despite the expected seasonal trends in ARDS prevalence (lower in summer and higher in winter and spring) the prevalence of PP did not differ accordingly.

Second, another possible reason to suspect an overestimation of PP is the choice and the number of the ICUs included in this work. In fact, the APRONET enrolled 141 ICUs from 20 countries (mostly European). Furthermore, most of the ICUs recruited were located in France, Spain and Italy which are the countries that have shown the higher interest in ARDS treatment and have published the larger studies on PP, so far.

Some concerns still arise when it comes to the choice of the patients to pronate and, even most important, the ones not to. Looking at the reasons for not pronating, stands out the clinician misunderstandings about the severity of hypoxemia (accounting for 64.3% of all cases). One of the most challenging issues of PP treatment for ARDS patients has always been the definition of the specific thresholds of PaO₂/FiO₂ that might benefit the most from this strategy.

The Proseva trial represents a cornerstone on this issue and the APRONET study seems to confirm the point. As previously pointed out, the 40% of patients meeting the Proseva criteria in this study had been pronated, reflecting the impact of this trial on the clinicians perception. This same impact may as well be reflected by the overall length of the PP treatment, that is now assessed on 18 (from 16 to 23) hours for the first session, showing a larger consensus on the evidence that duration of positioning consistently affects the efficacy of PP. But more interestingly, how can we explain the choice not to pronate the 60% of patients meeting the Proseva criteria of severe ARDS, and, even
more significant, how can we explain the choice to pronate a number of patients with mild or moderate ARDS?

One possible answer is that a substantial number of patients that showed a PaO$_2$/FiO$_2$ ratio <150 were not considered hypoxemic enough to undergo PP. Still, this doesn’t match with the 15 patients pronated with a P/F ratio between 295 and 171.

According to this scenario, we have to assume that there is still a deep confusion and a lack of homogeneity when it comes to recognition of the severity of ARDS and progression of treatments.

Consolidated evidence shows that the greatest benefit from each therapeutic strategy can be achieved only if applied to a specific level of ARDS progression (11).

Given that Lung Protective Ventilation should be the base-line of ARDS treatment from the start, patients with a P/F ratio between 200 and 150 should progressively be treated with higher levels of PEEP and neuromuscular blockade. Subsequently, PP represents the third line of treatment after which (in presence of a P/F ratio declining to <100) rescue treatments should be considered (12).

The second most important reason not to pronate (that could partially help to explain the 49 severe ARDS patients that were not pronated), is the hemodynamic instability. This element concurs at the idea that ARDS treatment strategies have not been fully understood and embraced by ICUs physicians, given that pronating have shown to improve hemodynamic rather than worsen it.

Lastly, looking at the possible reasons not to pronate a patient, stands out the undefined voice (others) that accounts for the 6% of the cases (44 patients). It is rational to think that this percentage could be referred to all the logistic and practical reasons that have always played an important role in the low application of PP, so far.

The rates of possible complications have been pointed out, in the past studies, as one of the criticisms in PP practice. The chance of endotracheal tube, drains or catheters removal, and the higher incidence of pressure sores may have accounted for a certain part of not considering PP as a feasible strategy. The Apronet study deviates from this tendency. Complications were reported in 12 of 101 pronated patients. Also in this case, these data can be interpreted as either due to (I) improvement of ICUs standards of practice thanks to a more frequent use of PP; (II) selection of ICUs that have always been more open to the PP practice and therefore have developed the skills to perform it in the most efficient and safe way.

With all these limitations, the APRONET study confirms the efficacy of PP. A significant improvement in oxygenation at the first session of PP was observed, with a reduction of driving pressure (with no variations on Vt). This could represent an interesting finding since driving pressure has been pointed as a strong predictor of mortality in ARDS patients. With all the limitations of the case, the APRONET study gives a first sight on the perception among clinicians of the use of PP.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References


